The United States will procure an additional 200 million doses of the vaccine manufactured by the Pfizer-BioNTech alliance, and has positioned itself for a serum against the variants, Pfizer said Friday.
To read also: Vaccination: deliveries of Pfizer down and AstraZeneca shunned by the French
These new doses will bring the total of orders from the United States to their population to 500 million doses, the company said in a press release. In detail, 110 million of these additional doses should be delivered by December 31, and the remaining 90 million doses by April 30, 2022. The United States has also put a purchase option on a next version of the vaccine, "
taking into account potential variants
", as well as new formulations of the vaccine, "
if they are available and authorized
" by health authorities, says Pfizer.
The Pfizer-BioNTech alliance affirmed at the beginning of July to plan to request "
in the coming weeks
" the authorization for a third dose of its vaccine, in the United States and in Europe in particular, after "
", in order to increase the effectiveness of his vaccine.
Read also: Covid-19: BioNTech / Pfizer will partially produce its vaccine in South Africa
US health officials have reacted cautiously, saying that "
Americans who have been fully immunized do not need a booster right now
", but saying they are ready "
to administer booster doses if and when the science will have shown that they are necessary
”. The spread of the Delta variant around the world, which initially appeared in India and the most contagious since the outbreak of the Covid-19 pandemic, is currently causing contamination to rise sharply.